Abstract
Metformin is an established staple drug in the management of Type 2 diabetes mellitus. In this systematic review, we sought to establish the clinical utility of metformin in a range of dermatological conditions. The pathophysiology of acne vulgaris and polycystic ovarian syndrome (PCOS) is well suited to the pharmacological profile of metformin, and we found evidence for its efficacy in managing these conditions. We found some evidence for the use of metformin particularly in acne and PCOS; however, the evidence base is of mixed quality. There is scope for clinicians to consider metformin as an adjunct therapy in acne and PCOS. There is generally insufficient evidence to recommend metformin in other dermatological conditions.
Original language | English |
---|---|
Journal | Clinical and Experimental Dermatology |
Volume | 48 |
Issue number | 2 |
Pages (from-to) | 73-79 |
Number of pages | 7 |
ISSN | 0307-6938 |
DOIs | |
Publication status | Published - Feb 2023 |
Bibliographical note
Publisher Copyright:© 2022 The Author(s). Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved.